Vivek K. Subbiah
Highly rated in
Highly rated in
Check Dr. Vivek K. Subbiah's experience treating your condition:
About Dr. Vivek K. Subbiah

Vivek Subbiah is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in Houston, Texas. Subbiah has been practicing medicine for over 21 years and is highly rated in 55 conditions, according to our data. His top areas of expertise are Medullary Thyroid Carcinoma, Adult Soft Tissue Sarcoma, Thyroid Cancer, Gamma Knife Radiosurgery, and Bone Marrow Transplant. He is licensed to treat patients in Texas. Subbiah is currently accepting new patients.

His clinical research consists of co-authoring 419 peer reviewed articles and participating in 36 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Vivek K. Subbiah it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Vivek K. Subbiah accepts the following insurance:

  •  Ambetter
1515 Holcombe Blvd, Houston, TX 77030
Background & Education
Graduate Institution
Other, 2002
Pediatric Hematology Oncology
Hematology Oncology
Pediatric Hematology-Oncology in TX
Hospital Affiliations
University Of Texas MD Anderson Cancer Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

36 Clinical Trials

An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
An Open-label, Single-Center, Phase 1b/2 Study to Evaluate the Safety of Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Malignancies After Progression on PD-1 or PD-L1 Targeted Antibodies
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers
A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies
A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
View 24 Less Clinical Trials -

419 Total Publications

Exportin(g) precision oncology beyond genomics with XPO1 inhibition.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors